PTO/SB/08a (08-03)
Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Appendix for the Popervisit Reduction Act of 1995, no persons are required to reach though 2017/10/2006, CISS 0605-2007.

Didder the Popervisit Reduction Act of 1995, no persons are required to required to a collection of internation unless 4 contains a valid OMS control number.

Application Number

Filing Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				First N	First Named Inventor Hans Adams			ns					
				Art Ur	nit			Т					
				Exam	iner Na	me							
				Attorn	Attorney Docket Number VKSWP0102U			s					
					U.S.	PATENTS					Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	sue Date Name of Patentee or Applicant of cited Document			Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	4661883		1987-0	1987-04-28 Nishızako et al.								
	2	5345119		1994-0	9-06	Khoury et	al.						
	3	4051545		1977-09-27		Kioss et a	ı.						
If you wish to add additional U.S. Patent citation information please click the Add button. Add													
			U.S.P.	ATENT	APPLI	CATION P	UBL	ICATI	ONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		Publication Date Name of Patentee or Applicant of cited Document		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1												
If you wish to add additional U.S. Published Application citation information please click the Add button. Add													
FOREIGN PATENT DOCUMENTS Remove													
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	ın		of Patent ant of cite nent	ee or d	where Re	or Relevant	
	1	197 25 317	DE			1998-12-1	0						

	Application Number		
	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Hans	Adams
Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	VKSWP0102US

If you wish	h to a	d additional Foreign Patent Document citation information please click the Add button Add	
		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), itile of the article (when appropriate), title of the (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	item Ts
	1		
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add	
		EXAMINER SIGNATURE	
Examiner	Signa	ure Date Considered	
*FYAMIN	FR: In	ial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	ugh a

1 See Kin Codes of USPTO Patent Documents at wear USPTO_CODY or MPEP 90.16.2 Either office that issued the document, by the Involved (WIPO Standard ST3).3 "For Just planese petral for contents, the architecture of the Superior representations preceded he serial representations are the petral document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Enginth Imagings the resistation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Please see 37 CFR	1.97 and 1.98 to make	the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(a/1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 137(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Don W. Bulson/	Date (YYYY-MM-DD)	2006-09-15
Name/Print	Don W. Bulson	Registration Number	28192

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is fol file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superinteed for Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.